BCA356 / Biocon - LARVOL DELTA

A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity (SITC 2022) - "Conclusions BCA356 specifically targets CAIX-expressing tumour cells and similar to wild type IL-12 cytokine, has the potential to reduce tumour proliferation with optimal activation of pro-inflammatory cytokines. Through these in vitro and in vivo studies, we demonstrate that BCA356 by its CAIX-targeted IL-12v delivery approach is both efficacious and safe."

Preclinical • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CA9 • CD8 • IFNG • IL12A • IL2 • STAT4

Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine, BCA356, at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Businesswire) - "Bicara intends to continue advancing BCA356 through Investigational New Drug (IND)-enabling studies and expects to submit an IND application by the end of 2023....BCA356 Data Highlights: Immunohistochemistry studies confirm high CAIX expression across tumor types, notably in clear cell renal carcinoma; BCA356 specifically targets CAIX-expressing tumor cells, and similar to wild type IL-12 cytokine, has the potential to reduce tumor proliferation with optimal activation of additional pro-inflammatory cytokines; BCA356 attenuated IFNγ release by stimulated peripheral blood mononuclear cells (PBMCs), activated NK cell and pSTAT4 expression in CD8 T cells as compared to IL-12 wild type...Efficacy studies in humanized and transgenic mice models confirmed that BCA356 is efficacious and safe in CAIX-overexpressing tumor bearing mice."

IND • Preclinical • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor